| Document |
Document Title |
|
WO/2023/198682A1 |
Compound of the general formula (Ia), (Ib) and (Ic) R50 and R60 are different form each other and are selected from the group consisting of -R70, -ZR70, -Z-OH, -Z-NH2, -Z-SH, -Z-OC(O)R70, -OC(O)R70, - COOH and its corresponding salts, -C...
|
|
WO/2023/196636A1 |
This application relates to methods of inhibiting the growth of microbes in and/or on plant-based products by treating the plant-based products with a composition including one or more ascarosides.
|
|
WO/2023/194941A1 |
Methods of preparing N-acetyllactosamine derivatives for use in the preparation 3'-O-glycosyl- and 2',3'-di-O-glycosyl-N-acetyllactosamine derivatives are described. The methods avoid the use of column chromatography and allow for the pr...
|
|
WO/2023/185505A1 |
A compound of a heparin trisaccharide structure and a preparation method therefor. The compound of the heparin trisaccharide structure has a single optical activity, and the core structure is Glc(1→4)IdoA(1→4)GlcNS. The compound can ...
|
|
WO/2023/191531A1 |
The present invention relates to a composition for preventing, ameliorating, or treating inflammatory diseases, allergic diseases, or sepsis. As a composition that inhibits the expression or activity of pro-inflammatory cytokines IL-8 or...
|
|
WO/2023/191513A1 |
The present invention relates to a composition comprising an imidazoline derivative and a sugar as active ingredients. According to the composition and a micelle according to an aspect, the solubility of the imidazoline derivative can be...
|
|
WO/2023/175140A1 |
The present invention relates to new carbohydrate derivatives with activity as mimetics of blood group A and B antigens. The present invention also relates to a method for preparing said carbohydrate derivatives and to a glycoconjugate c...
|
|
WO/2023/177970A1 |
A method for making highly soluble steviol glycoside compositions. The method can provide steviol glycoside solutions having a high concentration of dissolved steviol glycosides, and which exhibit long-term resistance to precipitation. V...
|
|
WO/2023/175536A1 |
Provided herein are compounds that contain one or more lipophilic moieties and can be used to prepare one or more lipophilic monomers. Also provided herein are lipophilic monomers that can be conjugated to one or more positions on at lea...
|
|
WO/2023/168520A1 |
The present disclosure relates generally to compounds, compositions, antibodies, and methods for raising and utilising an immune response in a subject, comprising administering to a subject an isolated or synthesised Pseudomonas aerugino...
|
|
WO/2023/166488A1 |
Provided herein are aminoglycoside compounds, such as compounds of Formula (I) and Formula (III), and pharmaceutically acceptable salts thereof, useful as therapeutic and/or prophylactic agents. The compounds may be useful in treating a ...
|
|
WO/2023/165381A1 |
Provided are an acyl-based statin compound with lipase inhibitory activity, a preparation method therefor, and use thereof in controlling body weight and treating obesity.
|
|
WO/2023/162946A1 |
The purpose of the present invention is to provide a medical agent which specifically binds to FAPα, is effective in the treatment and diagnosis of tumors or cancers expressing FAPα, for example, in the treatment and diagnosis of solid...
|
|
WO/2023/154302A1 |
The invention provides macromolecule-supported compounds of Formula I comprising a macromolecule linked by conjugation to one or more 8-sulfonyl-2-aminobenzazepine derivatives. The invention also provides 8-sulfonyl-2-aminobenzazepine de...
|
|
WO/2023/154307A1 |
The invention provides immunoconjugates of Formula. (I) comprising an antibody linked by conjugation to one or more 8-sulfonyl-2-aminobenzazepine derivatives. The invention also provides 8-sulfonyl-2-aminobenzazepine derivative intermedi...
|
|
WO/2023/143374A1 |
The present invention relates to a ligand, a method for preparing same, and a use thereof. The ligand has a structure represented by formula (I) or formula (II), wherein R1, R2, R3, and R4 are all linear structures with a glycosyl group ...
|
|
WO/2023/141693A1 |
The present disclosure relates to synthetic glycolipids of the formula (I): wherein • A represents (CH2)n with n being an integer from 2 to 10 or CH2-CH2-[O-CH2-CH2]m with m being an integer from 1 to 5; • B represents NR3 or OCH2, w...
|
|
WO/2023/141692A1 |
The present disclosure relates to synthetic glycolipids of the formula (I) wherein - A represents (CH2)n with n being an integer from 2 to 10 or CH2-CH2-[O-CH2-CH2]m with m being an integer from 1 to 5; - B represents NR3 or OCH2, with R...
|
|
WO/2023/144815A1 |
Provided herein are compositions for use in treatment fibrosis and in treatment of COVID-19, preferably moderate COVID-19, comprising Compound (1), or a pharmaceutically acceptable salt thereof. Also provided herein are methods for treat...
|
|
WO/2023/138664A1 |
The present invention is suitable for the technical field of nucleic acid drug delivery; specifically provided are a nucleic acid delivery compound, a liver-targeting nucleic acid ligand and the use thereof. Provided in the present inven...
|
|
WO/2023/138099A1 |
The present invention relates to a preparation method for miglitol. Specifically, the method of the present invention comprises: using a compound represented by formula VI as a raw material, subjecting the raw material to sulfonylation a...
|
|
WO/2023/135135A1 |
The present invention relates to new hyaluronic acid derivatives conjugated with molecules of natural origin endowed with anti-inflammatory and/or antioxidant properties and processes for manufacturing the same. The covalent link of thes...
|
|
WO/2023/131849A1 |
A composition comprising a mixture of two or more stereoisomers of a synthetic charged isoprenoid glycolipid of Formula (I), or a pharmaceutically acceptable salt thereof, in which n is 0 or 1, R and R' are independently hydrogen or hydr...
|
|
WO/2023/129737A1 |
Described herein are glycan compounds and particles comprising glycan compounds. The compounds and particles described herein are useful in methods of treating immune and inflammatory-related diseases. or a pharmaceutically acceptable sa...
|
|
WO/2023/120292A1 |
Provided is a method for producing a sulfonamide derivative, the method being characterized by including a step of causing a compound having a nitro group to react with a compound having a thiol group under light irradiation, and forming...
|
|
WO/2023/116301A1 |
The present invention relates to a method for preparing a liquid maltitol and a liquid polyol by using a maltitol chromatographic raffinate, comprising the following steps: hydrogenating a pretreated maltitol chromatographic raffinate to...
|
|
WO/2023/118500A1 |
Described herein are novel glycolipid surface-active compositions, products of, and methods of making the same.
|
|
WO/2023/121483A1 |
The present application is directed to immunomodulatory compositions comprising invariant NKT cell (iNKT cell) agonist compounds that induce expansion of tissue resident memory T-cells (Trm Cells) in combination with an immune stimulator...
|
|
WO/2023/115054A1 |
This application relates to methods of inhibiting the growth of human pathogenic bacteria in or on a plant by treating the seeds of the plant with an aqueous solution containing one or more ascarosides. The application also provides a me...
|
|
WO/2023/114781A1 |
Dust poses a significant threat to human and environmental health. In 2015, an estimated 4.2 million deaths, as well as numerous health issues, were attributed to dust. Unlike other major contaminant transport pathways (e.g., water, soil...
|
|
WO/2023/114778A1 |
The present invention is directed to polymers comprising glycolipids and methods for producing and using the same. In particular, the polymers of the invention comprise a polymer backbone and a plurality of glycolipid side chains. The gl...
|
|
WO/2023/114746A1 |
Embodiments of the present application relate to functionalized N-acetylgalactosamine-analogs, methods of making, and uses of the same. In particular, mono or trivalent N-acetylgalactosamine analogs may be prepared by utilizing a wide va...
|
|
WO/2023/102665A1 |
Describe herein are methods and products for increasing the secretion of extracellular vesicles (EVs) from a cell via ganglioside treatment. Such increased secretion may be used for example for increasing the removal of misfolded protein...
|
|
WO/2023/102658A1 |
Disclosed are novel glycosylated mescaline derivative compounds that exhibit selective binding to the HT1A receptor over HT2A receptor and pharmaceutical and recreational drug formulations containing the same. The compounds may be produc...
|
|
WO/2023/102659A1 |
Disclosed are novel mescaline derivative compounds, notably glycosylated isopropylamine derivatives of mescaline, and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting an iso...
|
|
WO/2023/099478A1 |
The present invention relates to a novel and efficient method for the production of sphingolipids via the N-acylation of lysosphingolipids. The method comprises the use of 1,3,5-triazine-based acylating agents, and is especially suitable...
|
|
WO/2023/099741A1 |
The present application relates to adjuvants and adjuvant-antigen conjugate vaccines based on a triterpene glycoside saponin scaffold incorporating an oxime group at position C4 of the triterpene domain and pharmaceutical compositions th...
|
|
WO/2023/099813A1 |
The disclosure relates to a method for producing anionic saccharides by reacting saccharide with a compound having a conjugated electron withdrawing group via oxa-Michael addition reaction for producing a derivatized saccharide followed ...
|
|
WO/2023/101389A1 |
The present invention relates to a method for producing a disaccharide using beta-glucosidase and a cofactor thereof and a composition for inducing the enzyme production of a strain of the genus Trichoderma, the composition comprising th...
|
|
WO/2023/099327A1 |
The present invention relates to a slow-release formulation. It relates also to the use of said repellent formulation, to a method of use thereof, and to a composition comprising said formulation. It further relates to PMD glucovanillin ...
|
|
WO/2023/094654A1 |
The present invention relates to polyol-derived compounds and processes preparing the same.
|
|
WO/2023/092188A1 |
Compounds and compositions comprising said compounds, which have agrichemical activity such as herbicides, insecticides, fungicides and plant growth regulators; and methods for the use of said compounds.
|
|
WO/2023/094699A1 |
The present disclosure relates to lipid anionic oligosaccharides and to the uses thereof in medicine, especially in the treatment of the pathologies associated with abnormal hyperphosphorylation of tau protein, such as Alzheimer's disease.
|
|
WO/2023/096904A2 |
Provided herein are compound of Formula (I) and (II), and pharmaceutically acceptable salts thereof. Also provided are methods of preparing the compounds, pharmaceutically acceptable compositions thereof, and methods of their use and tre...
|
|
WO/2023/090764A1 |
The present invention relates to a wallpaper composition and wallpaper from which a flavor ingredient is released by heat and, more particularly, to a wallpaper composition and wallpaper, comprising a compound which includes a moiety der...
|
|
WO/2023/091993A1 |
Provided herein are salts which intercalate into the DNA of a cell and are capable of crossing the blood brain barrier of the formula (I) wherein the variables are as defined herein. These salts may be show improved water solubility and/...
|
|
WO/2023/085363A1 |
This transdermal absorption-type patch is provided with a support and an adhesive agent layer laminated on the support. The adhesive agent layer contains: a solid tacrolimus-surfactant composite in which tacrolimus is covered with a surf...
|
|
WO/2023/083716A1 |
The present invention provides anthracycline-linker reagents for the preparation of therapeutic antibody-drug conjugate (ADC) compounds. The present invention also provides therapeutic antibody-drug conjugate (ADC) compounds comprising a...
|
|
WO/2023/083226A1 |
The present invention relates to α-salidroside, and a preparation method therefor and an application thereof. The present invention provides novel salidroside, i.e., α-salidroside. Compared with known β-salidroside, in terms of scaven...
|
|
WO/2023/081505A1 |
The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides formulations and pharmaceutical compositions comprising compounds of the prese...
|
